Glooko announced new data reflecting positive outcomes using its EndoTool platform for insulin dosing.
EndoTool, a leading software platform, offers capabilities for inpatient insulin dosing and glycemic management. The FDA-cleared platform delivers assistance in optimizing insulin dosing, using a patient-specific algorithm in real-time. It helps reduce the risk of hypoglycemia and helps hospitals meet CMS quality measures while streamlining clinical workflows.
Palo Alto, California-based Glooko said it aims to support patients and clinicians across the full continuum of care through a single integrated solution. The company added EndoTool to its portfolio of diabetes management technologies when it acquired Monarch Medical last year.
Glooko shared findings at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Las Vegas. Evidence reflected outcomes from a three-year retrospective analysis spanning from January 2023 through December 2025. The analysis included 17,838 patients and 362,901 blood glucose values.
Findings demonstrated that EndoTool IV achieved a 98% reduction in severe hypoglycemia across a large, 19-hospital health system as compared with historical paper protocols. The analysis also found that EndoTool IV recommended prophylactic carbohydrates that helped avoid 2,213 potential episodes of hypoglycemia, while severe hyperglycemia (blood glucose greater than 300 mg/dl) remained low at 0.17%.
Glooko said the study highlighted EndoTool’s value proposition around patient-specific insulin dosing.
“These data reinforce an important point for healthcare systems: safer inpatient glycemic management requires more than static protocols,” said Dr. Paul Chidester, medical director, EndoTool. “Hospitals need decision support that reflects how individual patients respond to insulin. EndoTool’s patient-specific dosing helps standardize care, reduce risk, and support frontline teams as glycemic safety becomes a more visible measure of performance.”
